Kaken Pharmaceutical Co., Ltd.
Notice Regarding Absorption-Type Merger of a Consolidated Subsidiary (Short-Form Merger)
Kaken Pharmaceutical Co., Ltd. resolved to absorb its consolidated subsidiary ARTham Therapeutics through a merger. The effective date is scheduled for 2026-12-31. After the merger, Kaken Pharmaceutical Co., Ltd. will be the surviving company and ARTham will be the dissolved company. No share allocation will occur. The impact going forward is expected to be minor.
Key Figures
- Number of Issued Shares: 44,139,730 shares
- Net Sales: 76,871 million yen
- Net Income Attributable to Owners of Parent: 2,144 million yen
AI要約
Overview of the Merger
Kaken Pharmaceutical Co., Ltd. resolved at a board meeting to effect an absorption-type merger with its consolidated subsidiary, ARTham Therapeutics Co., Ltd. The effective date is scheduled for 2026-12-31, with Kaken Pharmaceutical Co., Ltd. as the surviving company and ARTham as the dissolved company. No share allocation will occur for either party, and there will be no special consideration provided for ARTham's stock acquisition rights.
Future Impact and Schedule
This merger is with a consolidated subsidiary of Kaken Pharmaceutical Co., Ltd., and the impact on consolidated results is expected to be minor. The resolution and contract signing date is 2026-11-09, and the effective date is scheduled for 2026-12-31.
Kaken Pharmaceutical Co., Ltd.
Company overview · Stock price · Financial data · All IR
